


Claims

1. A pyrimidinyl compound
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]-
5 benzonitrile, a *N*-oxide, an addition salt, a quaternary amine or a stereochemically
isomeric form thereof.
2. A pyrimidinyl compound according to claim 1 wherein the pyrimidinyl compound is
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]-
10 benzonitrile.
3. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and
a therapeutically active amount of a pyrimidinyl compound according to claims 1 or 2.
- 15 4. A combination comprising a pyrimidinyl compound according to claims 1 or 2, and
an antiretroviral compound, wherein said antiretroviral compound comprises at least
one of a nucleoside reverse transcriptase inhibitor, a non-nucleoside reverse
transcriptase inhibitor, a TIBO compound, an α -APA compound, a TAT-inhibitor, a
protease inhibitor, an immunomodulating agent, and mixtures thereof.
20
5. A combination according to claim 4, wherein said nucleoside reverse transcriptase
inhibitor comprises at least one of zidovudine (3'-azido-3'-deoxythymidine, AZT),
didanosine (dideoxy inosine; ddI), zalcitabine (dideoxycytidine, ddC), lamivudine
(3'-thia-2'-3'-dideoxycytidine, 3TC), and mixtures thereof.
25
6. A combination according to claim 4, wherein said non-nucleoside reverse
transcriptase inhibitors comprises at least one of suramine, pentamidine, thymopentin,
castanospermine, efavirenz, dextran (dextran sulfate), foscarnet-sodium (trisodium
phosphono formate), nevirapine (11-cyclopropyl-5,11-dihydro-4-methyl-6*H*-dipyrido-
30 [3,2-*b* : 2',3'-*e*][1,4]diazepin-6-one), tacrine (tetrahydroaminoacridine), and mixtures
thereof.
7. A combination according to claim 4, wherein said TIBO compound comprises
(*S*)-8-chloro-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo-
35 [4,5,1-*jk*][1,4]benzodiazepine-2(1*H*)-thione.

8. A combination according to claim 4, wherein said α -APA compound comprises α -[(2-nitro-phenyl)amino]-2,6-dichlorobenzene-acetamide.
9. A combination according to claim 4, wherein said protease inhibitor comprises at least one of indinavir, ritanovir, saquinovir, ABT-378, and mixtures thereof.
10. A combination according to claim 4, comprising at least one of RO-5-3335, levamisole, and mixtures thereof.
11. A combination according to claim 5, further comprising a pharmaceutically acceptable carrier.
12. A combination according to claim 6, further comprising a pharmaceutically acceptable carrier.
13. A combination according to claim 7, further comprising a pharmaceutically acceptable carrier.
14. A combination according to claim 8, further comprising a pharmaceutically acceptable carrier.
15. A combination according to claim 9, further comprising a pharmaceutically acceptable carrier.
16. A combination according to claim 10, further comprising a pharmaceutically acceptable carrier.
17. A combination according to claim 4 wherein said pyrimidinyl compound and said antiretroviral compound are combined in a single preparation.
18. A combination according to claim 17, further comprising a pharmaceutically acceptable carrier.
19. A process for preparing a compound as claimed in claim 2, comprising reacting a compound of formula



with NH_3 in the presence of a reaction inert solvent.

20. A process according to claim 19, wherein said reacting is performed in the presence of a base.
21. A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a therapeutically effective amount of a compound according to claims 1 or 2.
22. A method of treating subjects suffering from HIV (Human Immunodeficiency Virus) infection comprising administering to the subject a therapeutically effective amount of a combination according to claim 4.